Literature DB >> 20238210

The role of NMDA receptors in the signal attenuation rat model of obsessive-compulsive disorder.

Noa Albelda1, Nitza Bar-On, Daphna Joel.   

Abstract

RATIONALE: In recent years, an increasing body of evidence points to the involvement of the glutamatergic system and specifically the glutamatergic ionotropic N-methyl-D-aspartate (NMDA) receptor in the pathophysiology of obsessive-compulsive disorder (OCD).
OBJECTIVES: To test the role of NMDA receptors in compulsive behavior using the signal attenuation rat model of OCD. In this model, 'compulsive' behavior is induced by attenuating a signal indicating that a lever-press response was effective in producing food.
METHODS: The NMDA antagonist, MK 801 (0.025-0.100 mg/kg) and the partial NMDA agonist, D-cycloserine (3-100 mg/kg) were administered to rats just before assessing their lever-press responding following signal attenuation (Experiments 1 and 2, respectively). Because the effects of signal attenuation are assessed under extinction conditions, drug doses that were effective in Experiments 1 and 2 were also tested in an extinction session of lever-press responding that was not preceded by signal attenuation (Experiment 3).
RESULTS: Systemic administration of D: -cycloserine (15 mg/kg) selectively decreased compulsive lever pressing, whereas systemic administration of MK 801 did not affect compulsive lever-pressing but dramatically increased resistance to extinction.
CONCLUSIONS: Activation of NMDA receptors may have an anti-compulsive effect in OCD patients.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20238210     DOI: 10.1007/s00213-010-1808-9

Source DB:  PubMed          Journal:  Psychopharmacology (Berl)        ISSN: 0033-3158            Impact factor:   4.530


  61 in total

1.  'Compulsive' lever pressing in rats is enhanced following lesions to the orbital cortex, but not to the basolateral nucleus of the amygdala or to the dorsal medial prefrontal cortex.

Authors:  Daphna Joel; Julia Doljansky; Daniela Schiller
Journal:  Eur J Neurosci       Date:  2005-04       Impact factor: 3.386

2.  Reversal of phencyclidine effects by a group II metabotropic glutamate receptor agonist in rats.

Authors:  B Moghaddam; B W Adams
Journal:  Science       Date:  1998-08-28       Impact factor: 47.728

Review 3.  The pathogenesis and treatment of obsessive-compulsive disorder.

Authors:  O T Dolberg; I Iancu; Y Sasson; J Zohar
Journal:  Clin Neuropharmacol       Date:  1996-04       Impact factor: 1.592

4.  A cybernetic model of obsessive-compulsive psychopathology.

Authors:  R K Pitman
Journal:  Compr Psychiatry       Date:  1987 Jul-Aug       Impact factor: 3.735

5.  Kinetic study of the interactions between the glutamate and glycine recognition sites on the N-methyl-D-aspartic acid receptor complex.

Authors:  T Priestley; J A Kemp
Journal:  Mol Pharmacol       Date:  1994-12       Impact factor: 4.436

6.  A transgenic model of comorbid Tourette's syndrome and obsessive-compulsive disorder circuitry.

Authors:  E J Nordstrom; F H Burton
Journal:  Mol Psychiatry       Date:  2002       Impact factor: 15.992

7.  'Compulsive' lever-pressing in rats is attenuated by the serotonin re-uptake inhibitors paroxetine and fluvoxamine but not by the tricyclic antidepressant desipramine or the anxiolytic diazepam.

Authors:  D Joel; E Ben-Amir; J Doljansky; S Flaisher
Journal:  Behav Pharmacol       Date:  2004-05       Impact factor: 2.293

8.  D-cycloserine facilitates extinction of conditioned alcohol-seeking behaviour in rats.

Authors:  Valentina Vengeliene; Falk Kiefer; Rainer Spanagel
Journal:  Alcohol Alcohol       Date:  2008 Nov-Dec       Impact factor: 2.826

9.  The NMDA positive modulator D-cycloserine inhibits dopamine-mediated behaviors in the rat.

Authors:  R Dall'Olio; R Rimondini; O Gandolfi
Journal:  Neuropharmacology       Date:  1994-01       Impact factor: 5.250

10.  The anticonvulsant activity of D-cycloserine is specific for tonic convulsions.

Authors:  S L Peterson; N D Schwade
Journal:  Epilepsy Res       Date:  1993-06       Impact factor: 3.045

View more
  12 in total

Review 1.  Glutamate abnormalities in obsessive compulsive disorder: neurobiology, pathophysiology, and treatment.

Authors:  Christopher Pittenger; Michael H Bloch; Kyle Williams
Journal:  Pharmacol Ther       Date:  2011-09-22       Impact factor: 12.310

Review 2.  The role of glutamate signaling in the pathogenesis and treatment of obsessive-compulsive disorder.

Authors:  Ke Wu; Gregory L Hanna; David R Rosenberg; Paul D Arnold
Journal:  Pharmacol Biochem Behav       Date:  2011-10-15       Impact factor: 3.533

3.  The role of the cholinergic system in the signal attenuation rat model of obsessive-compulsive disorder.

Authors:  Roni Yankelevitch-Yahav; Yankelevitch-Yahav Roni; Dapha Joel; Joel Daphna
Journal:  Psychopharmacology (Berl)       Date:  2013-05-18       Impact factor: 4.530

Review 4.  D-cycloserine augmentation in behavioral therapy for obsessive-compulsive disorder: a meta-analysis.

Authors:  Jing Xia; Yanqiu Du; Jiyang Han; Guo Liu; Xumei Wang
Journal:  Drug Des Devel Ther       Date:  2015-04-21       Impact factor: 4.162

Review 5.  Animal models of obsessive-compulsive disorder: utility and limitations.

Authors:  Pino Alonso; Clara López-Solà; Eva Real; Cinto Segalàs; José Manuel Menchón
Journal:  Neuropsychiatr Dis Treat       Date:  2015-08-04       Impact factor: 2.570

Review 6.  A selective review of glutamate pharmacological therapy in obsessive-compulsive and related disorders.

Authors:  Marco A Grados; Elizabeth B Atkins; Gabriela I Kovacikova; Erin McVicar
Journal:  Psychol Res Behav Manag       Date:  2015-04-28

7.  Comorbid obsessive-compulsive symptoms in schizophrenia: contributions of pharmacological and genetic factors.

Authors:  Frederike Schirmbeck; Mathias Zink
Journal:  Front Pharmacol       Date:  2013-08-09       Impact factor: 5.810

8.  Signal attenuation as a rat model of obsessive compulsive disorder.

Authors:  Koral Goltseker; Roni Yankelevitch-Yahav; Noa S Albelda; Daphna Joel
Journal:  J Vis Exp       Date:  2015-01-09       Impact factor: 1.355

9.  The hippocampus encodes delay and value information during delay-discounting decision making.

Authors:  Akira Masuda; Chie Sano; Qi Zhang; Hiromichi Goto; Thomas J McHugh; Shigeyoshi Fujisawa; Shigeyoshi Itohara
Journal:  Elife       Date:  2020-02-20       Impact factor: 8.140

Review 10.  Comorbid Obsessive-Compulsive Symptoms in Schizophrenia: Insight into Pathomechanisms Facilitates Treatment.

Authors:  Mathias Zink
Journal:  Adv Med       Date:  2014-06-11
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.